Autologous Exosome Pre-treatment for Nanoparticle Lung Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nanoparticle-based delivery systems face challenges in effectively targeting tumors and efficiently delivering therapeutic agents due to off-targeting cytotoxic effects and poor accumulation in desired tissues, particularly in overcoming the rapid sequestration by liver Kupffer cells, which hinders the delivery of therapeutic agents to lungs and tumors.
Innovation Solution
Administering autologous exosomes prior to nanoparticle delivery redirects nanoparticles from the liver to the lungs and tumors by inhibiting Kupffer cell uptake, utilizing exosomes to modulate the distribution of nanoparticles and enhance their accumulation in target tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nanoparticles are administered for therapeutic delivery, then therapeutic agents can be delivered to target tissues, but rapid sequestration by liver Kupffer cells occurs which hinders accumulation in lungs and tumors
Solution Approach 1:
The patent applies preliminary action by administering autologous exosomes 30 minutes before nanoparticle injection. This pre-treatment modifies the physiological environment to prevent rapid Kupffer cell uptake of nanoparticles, thereby improving nanoparticle accumulation in target tissues such as lungs and tumors while maintaining therapeutic delivery efficiency
Solution Approach 2:
The patent uses autologous exosomes as an intermediary substance that mediates between the administered nanoparticles and the liver Kupffer cells. The exosomes interact with Kupffer cells to reduce their uptake capacity for nanoparticles, thereby protecting nanoparticles from rapid sequestration and enabling improved accumulation in target tissues
2Reliability
If nanoparticles are used for cancer treatment, then therapeutic agents can be delivered, but off-targeting cytotoxic effects occur
Solution Approach 1:
The patent applies preliminary action by pre-administering autologous exosomes to modify the biodistribution environment before nanoparticle delivery. This ensures that subsequent nanoparticle administration achieves better target accumulation and reduced off-targeting, thereby improving cancer treatment efficacy while minimizing off-targeting cytotoxic effects
Solution Approach 2:
The patent uses autologous exosomes (derived from the patient's own blood) to create a feedback-based biodistribution modulation system. The exosomes reflect the patient's physiological state and selectively modify nanoparticle uptake patterns, providing patient-specific optimization that enhances target accumulation and reduces off-targeting cytotoxic effects
Data Source
AI summary
Provided are methods for treating tumors and/or cancers. In some embodiments, the methods relate to administering to a subject in need thereof an effective amount of a nanoparticle derived from an edible plant and an effective amount of an autologous exosome. Also provided are methods for enhancing accumulation of nanoparticles in the lungs of subjects, methods for delivering agents to the liver, brain, and/or bones of subjects, and methods for delivering agents across the blood-brain barrier of subjects.